Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment
Nutrients · 2024
DOI: 10.3390/nu16213686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Masato Hamasaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Non-alcoholic Fatty Liver Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Fatty acids are involved in some hepatic disorders. The proprotein convertase subtilisin kexin 9 (PCSK9) inhibits the uptake of low-density lipoproteins (LDLs), which contain lipids, into the liver and may thus be associated with nonalcoholic fatty liver disease (NAFLD), a cardiovascular disorder (CVD) risk. Statins reduce blood LDL–cholesterol (LDL-C) levels and CVD risk and can attenuate the development of NAFLD while increasing blood PCSK9 levels.
Methods
We investigated the correlation between PCSK9 and liver conditions in patients with familial hypercholesterolemia (FH), a CVD risk population with elevated blood LDL-C levels, under statin treatment. Blood tests for lipids, PCSK9, and liver function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) were performed in patients with FH taking statins (n = 25, mean age = 57 years, 12% of males). The ALT:AST ratio was used as a marker of NAFLD risk.
Results
The mean LDL-C level was 3.38 mmol/L, and the median PCSK9 level was 312 ng/mL. The median ALT:AST ratio was 0.88. A significant negative correlation was observed between the PCSK9 and ALT:AST ratio (β = −0.67, p < 0.05).
Conclusions
Their negative correlation might give a hypothetical insight into the effect of statin treatment on the development of NAFLD, in relation to PCSK9 behavior, in patients with FH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
- Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Fushimi-Ku, Kyoto 612-8555, Japan.
ORCID-Profile: Naoki Sakane, Kazuhiko Kotani
Zitieren
APA
Hamasaki, M., Sakane, N., & Kotani, K. (2024). Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. Nutrients. https://doi.org/10.3390/nu16213686
Vancouver
Hamasaki M, Sakane N, Kotani K. Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. Nutrients. 2024. doi:10.3390/nu16213686
BibTeX
@article{Hamasaki2024,
author = {Hamasaki, Masato and Sakane, Naoki and Kotani, Kazuhiko},
title = {Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16213686}
}
EUVIMED